bluebird bio (BLUE) to Present New Data from Three LentiGlobin Studies at ASH
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
BTIG Defends bluebird bio (BLUE) Amid ASH Abstracts Sell-Off
November 3, 2016 12:44 PM EDTBTIG is out in defense of bluebird bio (Nasdaq: BLUE) following release of ASH abstracts earlier this morning. The firm rates bluebird at Buy with a price target of $83.
The firm commented, BLUE has experienced a significant sell-off as a result of weak... More
bluebird bio (BLUE) ASH Abstract Data Fairly Consistent With Previously Published Data - Leerink
November 3, 2016 11:58 AM EDTLeerink Partners analyst Michael Schmidt reiterated an Outperform rating and $80 price target on bluebird bio (NASDAQ: BLUE) saying the ASH abstract data was fairly consistent with previously published data.
Schmidt commented, " This morning, abstracts for the upcoming American Society of Hematology (ASH) Annual Meeting were... More
Cantor Fitzgerald Reiterates Sell on bluebird bio (BLUE) Following ASH Abstracts
November 3, 2016 11:19 AM EDTCantor Fitzgerald analyst Elemer Piros reiterated a Sell rating and $37 price target on bluebird bio (NASDAQ: BLUE) following this morning's ASH abstracts.
Piros highlighted:
As telegraphed by the company at a recent investor/analyst day, at the upcoming ASH... More
